Photo credit © ChaunuPictures
(Boursier.com) — Mithras climbs 3% to 1.17 euros, while the company dedicated to women’s health announced the signing of a binding agreement for the marketing of DONESTA in Israel with Rafa Laboratories LTD, an Israeli pharmaceutical company.
DONESTA is Mithra’s next-generation investigational hormone therapy medicine containing estetrol (E4) for the treatment of menopausal symptoms.
Rafa Laboratories will hold exclusive commercial rights to DONESTA in Israel and the Palestinian territories upon signing of the final licensing and supply agreement, expected in the first quarter of 2024.
Mithra is eligible to receive a total of €2.05 million in sales-related milestones, as well as double-digit tiered royalties on annual net sales.
Portzamparc emphasizes that the market is “small”, but “the deal expands the group’s international coverage”. Enough to keep the file while aiming for a price of 1.20 euros.
©2023 Boursier.com